老年HIV感染者抗胆碱能药物使用与自报神经认知损伤:一项前瞻性队列研究
在瑞士HIV队列研究中,≥65岁HIV感染者中20%使用至少一种抗胆碱能药物;校正年龄、性别、CD4、最低CD4、病毒载量、依非韦伦使用和多重用药后,自报神经认知损伤与抑郁相关(OR=4.60),与使用至少一种抗胆碱能药物呈趋势(OR=1.69);在无抑郁亚组中,自报神经认知损伤与使用至少一种抗胆碱能药物相关(OR=2.51)。
要点
- ≥65岁HIV感染者中20%使用至少一种抗胆碱能药物,平均抗胆碱能评分为1.7±1.3。
- 校正混杂后,自报神经认知损伤与抑郁相关(OR=4.60;95%CI=2.62-8.09)。
- 无抑郁亚组中,自报神经认知损伤与使用至少一种抗胆碱能药物相关(OR=2.51;95%CI=1.31-4.80)。
核心结论
- 抗胆碱能药物在老年HIV感染者中常见,并参与自报神经认知损伤;抗胆碱能药物对神经认知损伤的影响需用神经认知测试进一步评估。
主要发现
- 99%参与者使用抗逆转录病毒治疗,非HIV药物平均5.1±3.6种,多重用药患病率50%。
- 校正年龄、性别、CD4、最低CD4、病毒载量、依非韦伦使用和多重用药后,自报神经认知损伤与抑郁相关(OR=4.60;95%CI=2.62-8.09),与使用至少一种抗胆碱能药物呈趋势(OR=1.69;95%CI=0.97-2.95)。
- 无抑郁亚组(n=911)中,自报神经认知损伤与使用至少一种抗胆碱能药物相关(OR=2.51;95%CI=1.31-4.80)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anticholinergic (ACH) medications have been associated with neurocognitive impairment, particularly in the elderly. This study determined prospectively the prevalence of prescribed ACH medications and their association with self-reported neurocognitive impairment (SRNI) in elderly people living with HIV (PLWH) of the Swiss HIV Cohort Study (SHCS). METHODS: A literature review was performed to identify ACH medications, which were scored 0 to 3 (higher score indicating more ACH burden). Prescriptions were reviewed in July 2019 for all SHCS participants ≥65 years old to assess the prevalence of ACH medications. Association between ACH burden and neurocognitive impairment was evaluated using the SHCS SRNI questions addressing memory loss, attention difficulties and slowing in reasoning. RESULTS: One thousand and nineteen PLWH (82% male) with a median age of 70 (IQR = 67-74) years were included. Most participants were on ART (99%). The average number of non-HIV drugs was 5.1 ± 3.6, representing a polypharmacy prevalence of 50%. Two hundred participants (20%) were on ≥1 ACH medication, with an average ACH score of 1.7 ± 1.3. SRNI, adjusted for age, sex, CD4, nadir CD4, viral load, efavirenz use and polypharmacy, was associated with depression (OR = 4.60; 95% CI = 2.62-8.09) and a trend was observed with being on ≥1 ACH medication (OR = 1.69; 95% CI = 0.97-2.95). In a subgroup analysis of participants without depression (n = 911), SRNI was associated with the use of ≥1 ACH medication (OR = 2.51; 95% CI = 1.31-4.80). CONCLUSIONS: ACH medication use is common in elderly PLWH and contributes to SRNI. The effect of ACH medications on neurocognitive impairment warrants further evaluation using neurocognitive tests.
引用
- Jakeman B, Scherrer A, Battegay M, et al. Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. J Antimicrob Chemother. 2022. PMID: 34734255. doi:10.1093/jac/dkab386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。